The note says ESDS Software Solutions led H1 FY27 IPO gains with a 233.7% return.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
All houses
HDFC Securities
Motilal Oswal
Mirae Asset Sharekhan
Tata Asset Management
Jainam
India IPO
GEPL Capital
Way2Wealth
SBICAP Securities
Angel One
Axis Securities
ICICI Direct Research Retail
Formerly known as Way2Wealth
Religare
Arete Securities
ICICI Direct
Way2Wealth Securities
ICICI Securities
quant Mutual Fund
Kotak Securities
JM Financial
ICICI Securities – Retail
Ventura Securities
Global Markets by Vested
Prabhudas Lilladher
ITC Hotels
Elara Securities
Exterminators PLC
Emkay Global
Industrial Asphalts
Private Client Group Research summarized from KIE research report
Kahawatte Plantations PLC
2566 notes · all time
The report initiates coverage on Molbio Diagnostics with a BUY rating and a 12-month target price of INR1,800, implying about 19-21% upside, based on a 45x 12-month forward P/E (a 20% premium to the sector multiple of 36x), citing its differentiated R&D-driven business model and expected 23% revenue CAGR and 50% PAT CAGR over FY26-29E, while flagging customer concentration, high TB revenue dependence, regulatory delays and working-capital intensity as key risks.
Read this note →The report reiterates a BUY rating with a target price of Rs 1,225, stating that the appointment of Anup Bagchi as MD & CEO removes leadership overhang and should help restore investor and customer confidence, with re-rating expected as business execution improves and FPI outflows moderate.
Read this note →The report says it received Mainboard approval for a fresh issue of 57.62 lakh shares and an OFS of 15.15 lakh shares.
Read this note →The report says it received Mainboard approval for a fresh issue of 1.187 crore shares and an OFS of 0.728 crore shares.
Read this note →The report says it received Mainboard approval with issue details marked confidential.
Read this note →The report says it received Mainboard DRHP approval for a ₹550 crore fresh issue.
Read this note →The report says it proposed an ₹800 crore fresh issue along with OFS of ₹200 crore.
Read this note →The report says it proposed a ₹550 crore fresh issue along with OFS of ₹450 crore.
Read this note →The report says it proposed a ₹525 crore fresh issue cum OFS of ₹200 crore.
Read this note →The report says it proposed a ₹500 crore fresh issue cum OFS of 0.15 crore shares.
Read this note →The report says it filed a Mainboard DRHP with a ₹600 crore fresh issue and up to 1 crore shares as promoter OFS.
Read this note →The report says it filed a DRHP with a ₹600 crore fresh issue.
Read this note →The report says it filed a Mainboard DRHP with an ₹850 crore fresh issue plus ₹150 crore OFS, the largest disclosed filing of the week.
Read this note →The report says it launched an SME issue of ₹23.45 crore.
Read this note →The report says it launched an SME issue of ₹21.78 crore.
Read this note →The report says it launched an SME issue of ₹20.18 crore.
Read this note →The report says it launched an SME issue of ₹14.01 crore.
Read this note →The report says it launched an issue of ₹33.98 crore.
Read this note →The report says it launched an issue of ₹55.08 crore.
Read this note →The report says it launched an issue of ₹90.17 crore.
Read this note →The report says it launched an issue of ₹73.26 crore.
Read this note →The report says it proposed an issue size of ₹81.79 crore.
Read this note →The report says it proposed an issue size of ₹108.35 crore.
Read this note →The report says it launched an issue of ₹178 crore.
Read this note →